ClinicalTrials.gg
CompletedNCT04251156STEP7Updated Jan 29, 2026Results posted

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

A Phase 3 interventional study of Semaglutide and Placebo (semaglutide) in Overweight, Obesity and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 33 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 144 studies testing semaglutide in Obesity — 69 open to participants now, 78 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
25th of 144
375 · median 100
Started
2020
with 3 others
Phase 3
42 of 144
10 open now
Registered
23rd of 144
by date
Lead sponsor
41 of 144
Novo Nordisk A/S

Among the 144 studies testing semaglutide in Obesity, this one is the 25th largest by enrollment, is one of 4 that started in 2020, is one of 42 in phase 3, and was the 23rd registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

69 of the 144 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

64 more — sign in →

By country, each count listing its studies:

All 69 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine participants will have talks with study staff about healthy food choices, how to be more physically active and what else they can do to lose weight. Participants will either get semaglutide or "dummy medicine" - which treatment is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm.• The study will last for about 1 year. Participants will have 11 clinic visits and 8 phone calls with the study doctor. Participants will have 3 clinic visits where they cannot eat and drink (water is allowed) for up to 8 hours before the visit and 1 clinic visit where they cannot eat and drink for up to 2 hours before the visit. (4 visits and 1 visit, respectively, if they have type 2 diabetes (T2D)). Participants will have 4 clinic visits where they will have blood samples taken. (5 visits if they have T2D). For China: Participants will have 9 clinic visits where they will have blood samples taken. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

03

Conditions studied

  • Overweight
  • Obesity
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Obesity Reclassified

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 375 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age 18 years or older at the time of signing
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

For subjects without T2D at screening:

  • (BMI) of :
  • greater than or equal to 30 kg/m\^2
  • greater than or equal to 27 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

For subjects with T2D at screening:

  • Diagnosed with T2D above or equal to 180 days prior to the day of screening
  • Treated with either:
  • diet and exercise alone or
  • stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic medications alone or in any combination (metformin, α-glucosidase inhibitor (AGI), SU, glinides, SGLT2i or glitazone) according to local label
  • 7.0-10.0% (53-86 mmol/mol) (both inclusive)
  • BMI greater than or equal to 27 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • A self-reported change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records

For subjects without T2D at screening:

- equal to or above 6.5% (48 mmol/mol) as measured by the central laboratory at screening

For subjects with T2D at screening :

  • Renal impairment measured as estimated (eGFR) value of below 30 mL/min/1.73 m\^2 (below 60 mL/min/1.73 m\^2 in subjects treated with SGLT2i) according to CKDEPI creatinine equation as defined by KDIGO 2012 by the central laboratory at screening
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Once-weekly injections of gradually increased doses of semaglutide

    Drug: Semaglutide

  • Placebo comparator
    Placebo (semaglutide)

    Once-weekly injections of gradually increased doses of semaglutide placebo

    Drug: Placebo (semaglutide)

Interventions

  • Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg

  • DrugPlacebo (semaglutide)

    Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Body Weight (Percentage [%])

    Change from baseline at week 0 to week 44 in body weight (%) is presented.The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  2. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)

    Number of participants who achieved \>=5% weight reduction at week 44 for in-trial observation period is presented.In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

Secondary outcomes

  1. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)

    Number of participants who achieved \>=10% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  2. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)

    Number of participants who achieved \>=15% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  3. Change From Baseline in Waist Circumference

    Change in waist circumference from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  4. Change From Baseline in Body Weight (Kilogram [kg])

    Change in body weight from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  5. Change From Baseline in Body Mass Index (BMI)

    Change in BMI from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  6. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)

    Number of participants who achieved \>=20% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  7. Change From Baseline in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  8. Change From Baseline in Short Form-36 (SF-36) - Physical Functioning Score

    SF-36 is a 36-item participants-reported survey of participants health that measures the partici-pants overall health-related quality of life (HRQoL). SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This outcome measure shows results for 'physical functioning domain'. Physical function domain score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline (week 0) in the domain scores were evaluated at week 44. These outcome measures were evaluated based on data from in-trial observation period which is the uninterrupted time interval from (week 0) to (week 51).

    Time frame: Baseline (week 0), week 44

  9. Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score

    The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite and physical function domain scores range from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  10. Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%])

    Change in glycosylated haemoglobin (HbA1c) (%) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  11. Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol])

    Change in HbA1c (mmol/mol) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  12. Change From Baseline in Fasting Plasma Glucose (FPG) (Milligrams Per Deciliter [mg/dL])

    Change in fasting plasma glucose (mg/dL) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  13. Change From Baseline in FPG (Millimoles Per Liter [mmol/L])

    Change in FPG (mmol/L) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  14. Change From Baseline in Fasting Serum Insulin: Ratio to Baseline

    Change in fasting serum insulin measured as milli-international units per milliliter (mIU/mL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  15. Change From Baseline in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  16. Change From Baseline in Total Cholesterol: Ratio to Baseline

    Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  17. Change From Baseline in High-Density Lipoproteins (HDL)-Ratio to Baseline

    Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  18. Change From Baseline in Low-Density Lipoproteins (LDL)-Ratio to Baseline

    Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  19. Change From Baseline in Very Low-Density Lipoproteins (VLDL)-Ratio to Baseline

    Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  20. Change From Baseline in Free Fatty Acids-Ratio to Baseline

    Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  21. Change From Baseline in Triglycerides-Ratio to Baseline

    Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  22. Change From Baseline in SF-36 All Domains (Except Physical Functioning) and 2 Component Summary Scores

    SF-36 is a 36-item participant-reported survey of health that measures the overall HRQoL. SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical and mental component summary). This outcome measure shows results for all domains (except physical functioning) and 2 component summary scores. The score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline week 0 in domain and component summary scores were evaluated at week 44 based on data from in-trial observation period which is uninterrupted time interval from (week 0) to (week 51).

    Time frame: Baseline (week 0), week 44

  23. Change From Baseline in IWQOL-Lite for Physical Domain Score, Psychological Domain Score and Total Score

    The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores for physical domain score, psychosocial domain score and total score ranges from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical and psychosocial domains, and for total'. The outcome measure was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  24. Number of Participants Who Achieved Responder Definition Value for SF-36 Physical Functioning Score (Yes/No)

    The number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 44 weeks was determined based on 3.7 threshold. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using participant global rating anchor questionnaires to reflect participants own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  25. Number of Participants Who Achieved Responder Definition Value For IWQoL-Lite for CT Physical Function (5-items) Score (Yes/No)

    The number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 44 weeks was determined based on thresholds of 14.6. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants own perspective based on FDA recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  26. Number of Participants With Type 2 Diabetes (T2D) Who Achieved HbA1c Less Than (<) 7.0 Percent (%) (53 mmol/Mol)

    Number of participants with T2D who achieved HbA1c \< 7% (53 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than the 7% and "No" infers the number of participants who have not achieved HbA1c values less than the 7%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  27. Number of Participants With T2D Who Achieved HbA1c Less Than or Equal to (<=) 6.5% (48 mmol/Mol)

    Number of participants with T2D who achieved HbA1c \<= 6.5% (48 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than or equal to 6.5% and "No" infers the number of participants who have not achieved HbA1c values less than or equal to 6.5%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: At week 44

  28. Change From Baseline in Glycaemic Category (Normo-Glycaemia, Pre-Diabetes, T2D) in Participants With no T2D at Baseline

    Change from baseline in number of participants in glycaemic categories (normo-glycaemia, pre-diabetes and type 2 diabetes) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  29. Change From Baseline in Number of Participants With Antihypertensive Medication (Decrease, No Change, Increase)

    Change from baseline in number of participants in antihypertensive medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  30. Change From Baseline in Number of Participants With Lipid-Lowering Medication (Decrease, No Change, Increase)

    Change from baseline in number of participants in lipid-lowering medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  31. Change From Baseline in Number of Participants With Concomitant Oral Antidiabetic Medication (Decrease, No Change, Increase) in Participants With No T2D at Baseline

    Change from basline in number of participants with concomitant oral antidiabetic medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  32. Change From Baseline in Number of Participants in Fatty Liver Index (FLI) Score Category

    Change from baseline in number of participants in fatty liver index (FLI) at baseline (week 0) to week 44 are presented. The fatty liver index is based on an algorithm including body mass index, waist circumference, triglycerides and gamma-glutamyl-transferase. The FLI scores less than (\<) 30 indicates no hepatic steatosis (no fatty liver), FLI greater than or equal to (\>=) 30 to less than (\<) 60 indicates intermediate status of hepatic steatosis and \>=60 indicates severe/worse hepatic steatosis. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  33. Number of Participants Who From Randomization Permanently Discontinued Randomized Trial Product

    Number of participants who permanently discontinued randomized trial product from baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

    Time frame: Baseline (week 0), week 44

  34. Time to Permanent Discontinuation of Randomized Trial Product (Weeks)

    Time to permanent discontinuation of randomised trial product from baseline (week 0) to week 44 is reported. Participants who permanently discontinued the randomised trial product during the in-trial observation period were only included in the analysis. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to date of last contact with trial site (week 51).

    Time frame: Baseline (week 0), week 44

  35. Number of Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.

    Time frame: Baseline (week 0), week 51

  36. Number of Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 51 is presented based on the on-treatment observation, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.

    Time frame: Baseline (week 0), week 51

  37. Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes (Yes/No) in Participants With T2D at Week 0

    Hypoglycaemic episodes with onset during on-treatment observation period were considered treatment-emergent. Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemia episodes in participants with T2D at week 0 with onset during on-treatment observation period were presented.

    Time frame: Baseline (week 0), week 51

  38. Change From Baseline in Pulse

    Change in pulse from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

    Time frame: Baseline (week 0), week 44

  39. Change From Baseline in Amylase: Ratio to Baseline

    Change in amylase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

    Time frame: Baseline (week 0), week 44

  40. Change From Baseline in Lipase: Ratio to Baseline

    Change in lipase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

    Time frame: Baseline (week 0), week 44

  41. Change From Baseline in Calcitonin: Ratio to Baseline

    Change in calcitonin measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

    Time frame: Baseline (week 0), week 44

08

Results

Posted Nov 29, 2024

Participant flow

The trial was conducted at 28 sites in 3 countries as follows (all sites screened and randomized): Region China (includes China mainland and Hong Kong) China mainland (23 sites) and Hong Kong (1 site), Brazil (2 sites) and South Korea (2 sites).

Participant flow — Overall Study
MilestoneSemaglutide 2.4 mgPlacebo
Started249126
Full analysis set (fas)249126
Safety analysis set (sas)249126
Treated249126
Completed244121
Not completed55
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject44

Outcome measures

PrimaryChange From Baseline in Body Weight (Percentage [%])

Change from baseline at week 0 to week 44 in body weight (%) is presented.The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Percentage change
Change From Baseline in Body Weight (Percentage [%])
Percentage changeSemaglutide 2.4 mgPlacebo
Change From Baseline in Body Weight (Percentage [%])-12.5 ± 7.4-3.6 ± 5.9
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -8.47 · 95% CI -10.17 to -6.76
PrimaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)

Number of participants who achieved \>=5% weight reduction at week 44 for in-trial observation period is presented.In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes20336
No3580
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 13.07 · 95% CI 7.40 to 23.10
SecondaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)

Number of participants who achieved \>=10% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes15112
No87104
SecondaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)

Number of participants who achieved \>=15% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes827
No156109
SecondaryChange From Baseline in Waist Circumference

Change in waist circumference from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Centimeter (cm)
Change From Baseline in Waist Circumference
Centimeter (cm)Semaglutide 2.4 mgPlacebo
Change From Baseline in Waist Circumference-11.1 ± 7.2-3.8 ± 5.8
SecondaryChange From Baseline in Body Weight (Kilogram [kg])

Change in body weight from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Kilogram (kg)
Change From Baseline in Body Weight (Kilogram [kg])
Kilogram (kg)Semaglutide 2.4 mgPlacebo
Change From Baseline in Body Weight (Kilogram [kg])-11.9 ± 7.3-3.4 ± 6.0
SecondaryChange From Baseline in Body Mass Index (BMI)

Change in BMI from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Kilograms per square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
Kilograms per square meter (kg/m^2)Semaglutide 2.4 mgPlacebo
Change From Baseline in Body Mass Index (BMI)-4.3 ± 2.6-1.2 ± 2.1
SecondaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)

Number of participants who achieved \>=20% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes342
No204114
SecondaryChange From Baseline in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure
Millimeters of mercury (mmHg)Semaglutide 2.4 mgPlacebo
Change From Baseline in Systolic Blood Pressure-7 ± 12-2 ± 12
SecondaryChange From Baseline in Short Form-36 (SF-36) - Physical Functioning Score

SF-36 is a 36-item participants-reported survey of participants health that measures the partici-pants overall health-related quality of life (HRQoL). SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This outcome measure shows results for 'physical functioning domain'. Physical function domain score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline (week 0) in the domain scores were evaluated at week 44. These outcome measures were evaluated based on data from in-trial observation period which is the uninterrupted time interval from (week 0) to (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Score on a scale
Change From Baseline in Short Form-36 (SF-36) - Physical Functioning Score
Score on a scaleSemaglutide 2.4 mgPlacebo
Change From Baseline in Short Form-36 (SF-36) - Physical Functioning Score1.3 ± 4.70.2 ± 5.7
SecondaryChange From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score

The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite and physical function domain scores range from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Score on a scale
Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score
Score on a scaleSemaglutide 2.4 mgPlacebo
Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score8.0 ± 16.42.3 ± 18.5
SecondaryChange From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%])

Change in glycosylated haemoglobin (HbA1c) (%) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Percentage of HbA1c
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%])
Percentage of HbA1cSemaglutide 2.4 mgPlacebo
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%])-0.8 ± 0.8-0.1 ± 0.8
SecondaryChange From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol])

Change in HbA1c (mmol/mol) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Millimoles per mole (mmol/mol)
Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol])
Millimoles per mole (mmol/mol)Semaglutide 2.4 mgPlacebo
Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol])-8.9 ± 9.2-1.3 ± 8.3
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) (Milligrams Per Deciliter [mg/dL])

Change in fasting plasma glucose (mg/dL) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG) (Milligrams Per Deciliter [mg/dL])
Milligrams per deciliter (mg/dL)Semaglutide 2.4 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) (Milligrams Per Deciliter [mg/dL])-18.9 ± 25.3-1.1 ± 18.7
SecondaryChange From Baseline in FPG (Millimoles Per Liter [mmol/L])

Change in FPG (mmol/L) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Millimoles per litre (mmol/L)
Change From Baseline in FPG (Millimoles Per Liter [mmol/L])
Millimoles per litre (mmol/L)Semaglutide 2.4 mgPlacebo
Change From Baseline in FPG (Millimoles Per Liter [mmol/L])-1.1 ± 1.4-0.1 ± 1.0
SecondaryChange From Baseline in Fasting Serum Insulin: Ratio to Baseline

Change in fasting serum insulin measured as milli-international units per milliliter (mIU/mL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of fasting serum insulin
Change From Baseline in Fasting Serum Insulin: Ratio to Baseline
Ratio of fasting serum insulinSemaglutide 2.4 mgPlacebo
Change From Baseline in Fasting Serum Insulin: Ratio to Baseline0.76 ± 57.30.98 ± 62.9
SecondaryChange From Baseline in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure
mmHgSemaglutide 2.4 mgPlacebo
Change From Baseline in Diastolic Blood Pressure-4 ± 9-1 ± 9
SecondaryChange From Baseline in Total Cholesterol: Ratio to Baseline

Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of total cholesterol
Change From Baseline in Total Cholesterol: Ratio to Baseline
Ratio of total cholesterolSemaglutide 2.4 mgPlacebo
Change From Baseline in Total Cholesterol: Ratio to Baseline0.94 ± 17.51.04 ± 17.5
SecondaryChange From Baseline in High-Density Lipoproteins (HDL)-Ratio to Baseline

Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of HDL
Change From Baseline in High-Density Lipoproteins (HDL)-Ratio to Baseline
Ratio of HDLSemaglutide 2.4 mgPlacebo
Change From Baseline in High-Density Lipoproteins (HDL)-Ratio to Baseline1.05 ± 15.51.08 ± 16.6
SecondaryChange From Baseline in Low-Density Lipoproteins (LDL)-Ratio to Baseline

Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of LDL
Change From Baseline in Low-Density Lipoproteins (LDL)-Ratio to Baseline
Ratio of LDLSemaglutide 2.4 mgPlacebo
Change From Baseline in Low-Density Lipoproteins (LDL)-Ratio to Baseline0.97 ± 33.01.04 ± 29.0
SecondaryChange From Baseline in Very Low-Density Lipoproteins (VLDL)-Ratio to Baseline

Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of VLDL
Change From Baseline in Very Low-Density Lipoproteins (VLDL)-Ratio to Baseline
Ratio of VLDLSemaglutide 2.4 mgPlacebo
Change From Baseline in Very Low-Density Lipoproteins (VLDL)-Ratio to Baseline0.71 ± 45.30.96 ± 44.3
SecondaryChange From Baseline in Free Fatty Acids-Ratio to Baseline

Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of free fatty acids
Change From Baseline in Free Fatty Acids-Ratio to Baseline
Ratio of free fatty acidsSemaglutide 2.4 mgPlacebo
Change From Baseline in Free Fatty Acids-Ratio to Baseline0.91 ± 66.91.05 ± 69.7
SecondaryChange From Baseline in Triglycerides-Ratio to Baseline

Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of triglycerides
Change From Baseline in Triglycerides-Ratio to Baseline
Ratio of triglyceridesSemaglutide 2.4 mgPlacebo
Change From Baseline in Triglycerides-Ratio to Baseline0.71 ± 50.20.96 ± 52.6
SecondaryChange From Baseline in SF-36 All Domains (Except Physical Functioning) and 2 Component Summary Scores

SF-36 is a 36-item participant-reported survey of health that measures the overall HRQoL. SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical and mental component summary). This outcome measure shows results for all domains (except physical functioning) and 2 component summary scores. The score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline week 0 in domain and component summary scores were evaluated at week 44 based on data from in-trial observation period which is uninterrupted time interval from (week 0) to (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Score on a scale
Change From Baseline in SF-36 All Domains (Except Physical Functioning) and 2 Component Summary Scores
Score on a scaleSemaglutide 2.4 mgPlacebo
Role-Physical0.5 ± 5.1-0.8 ± 6.3
Bodily Pain-0.3 ± 7.1-1.2 ± 7.3
General Health3.2 ± 7.61.6 ± 7.6
Vitality0.3 ± 7.8-1.1 ± 6.7
Social Functioning-0.5 ± 5.6-0.5 ± 5.0
Role-Emotional0.5 ± 7.0-0.9 ± 5.9
Mental Health-0.1 ± 7.4-1.8 ± 7.1
Physical component summary1.4 ± 5.20.4 ± 5.5
Mental component summary-0.3 ± 7.1-1.5 ± 6.1
SecondaryChange From Baseline in IWQOL-Lite for Physical Domain Score, Psychological Domain Score and Total Score

The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores for physical domain score, psychosocial domain score and total score ranges from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical and psychosocial domains, and for total'. The outcome measure was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Score on a scale
Change From Baseline in IWQOL-Lite for Physical Domain Score, Psychological Domain Score and Total Score
Score on a scaleSemaglutide 2.4 mgPlacebo
Physical7.2 ± 16.32.0 ± 18.3
Psychosocial12.0 ± 17.34.8 ± 17.4
Total10.3 ± 15.43.8 ± 16.2
SecondaryNumber of Participants Who Achieved Responder Definition Value for SF-36 Physical Functioning Score (Yes/No)

The number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 44 weeks was determined based on 3.7 threshold. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using participant global rating anchor questionnaires to reflect participants own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Responder Definition Value for SF-36 Physical Functioning Score (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes6927
No16889
SecondaryNumber of Participants Who Achieved Responder Definition Value For IWQoL-Lite for CT Physical Function (5-items) Score (Yes/No)

The number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 44 weeks was determined based on thresholds of 14.6. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants own perspective based on FDA recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Responder Definition Value For IWQoL-Lite for CT Physical Function (5-items) Score (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes8322
No15393
SecondaryNumber of Participants With Type 2 Diabetes (T2D) Who Achieved HbA1c Less Than (<) 7.0 Percent (%) (53 mmol/Mol)

Number of participants with T2D who achieved HbA1c \< 7% (53 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than the 7% and "No" infers the number of participants who have not achieved HbA1c values less than the 7%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants With Type 2 Diabetes (T2D) Who Achieved HbA1c Less Than (<) 7.0 Percent (%) (53 mmol/Mol)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes578
No520
SecondaryNumber of Participants With T2D Who Achieved HbA1c Less Than or Equal to (<=) 6.5% (48 mmol/Mol)

Number of participants with T2D who achieved HbA1c \<= 6.5% (48 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than or equal to 6.5% and "No" infers the number of participants who have not achieved HbA1c values less than or equal to 6.5%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants With T2D Who Achieved HbA1c Less Than or Equal to (<=) 6.5% (48 mmol/Mol)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes514
No1124
SecondaryChange From Baseline in Glycaemic Category (Normo-Glycaemia, Pre-Diabetes, T2D) in Participants With no T2D at Baseline

Change from baseline in number of participants in glycaemic categories (normo-glycaemia, pre-diabetes and type 2 diabetes) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Count of participants · Participants
Change From Baseline in Glycaemic Category (Normo-Glycaemia, Pre-Diabetes, T2D) in Participants With no T2D at Baseline
ParticipantsSemaglutide 2.4 mgPlacebo
Normo-glycaemia15853
Pre-diabetes1529
Diabetes02
SecondaryChange From Baseline in Number of Participants With Antihypertensive Medication (Decrease, No Change, Increase)

Change from baseline in number of participants in antihypertensive medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Count of participants · Participants
Change From Baseline in Number of Participants With Antihypertensive Medication (Decrease, No Change, Increase)
ParticipantsSemaglutide 2.4 mgPlacebo
Decreased82
No change5723
Increased94
SecondaryChange From Baseline in Number of Participants With Lipid-Lowering Medication (Decrease, No Change, Increase)

Change from baseline in number of participants in lipid-lowering medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Count of participants · Participants
Change From Baseline in Number of Participants With Lipid-Lowering Medication (Decrease, No Change, Increase)
ParticipantsSemaglutide 2.4 mgPlacebo
Decreased31
No change3113
Increased14
SecondaryChange From Baseline in Number of Participants With Concomitant Oral Antidiabetic Medication (Decrease, No Change, Increase) in Participants With No T2D at Baseline

Change from basline in number of participants with concomitant oral antidiabetic medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Count of participants · Participants
Change From Baseline in Number of Participants With Concomitant Oral Antidiabetic Medication (Decrease, No Change, Increase) in Participants With No T2D at Baseline
ParticipantsSemaglutide 2.4 mgPlacebo
Decreased162
No change3516
Increased16
SecondaryChange From Baseline in Number of Participants in Fatty Liver Index (FLI) Score Category

Change from baseline in number of participants in fatty liver index (FLI) at baseline (week 0) to week 44 are presented. The fatty liver index is based on an algorithm including body mass index, waist circumference, triglycerides and gamma-glutamyl-transferase. The FLI scores less than (\<) 30 indicates no hepatic steatosis (no fatty liver), FLI greater than or equal to (\>=) 30 to less than (\<) 60 indicates intermediate status of hepatic steatosis and \>=60 indicates severe/worse hepatic steatosis. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Count of participants · Participants
Change From Baseline in Number of Participants in Fatty Liver Index (FLI) Score Category
ParticipantsSemaglutide 2.4 mgPlacebo
<30678
30<= to <606217
>=6010788
SecondaryNumber of Participants Who From Randomization Permanently Discontinued Randomized Trial Product

Number of participants who permanently discontinued randomized trial product from baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Count of participants · Participants
Number of Participants Who From Randomization Permanently Discontinued Randomized Trial Product
ParticipantsSemaglutide 2.4 mgPlacebo
Number of Participants Who From Randomization Permanently Discontinued Randomized Trial Product1816
SecondaryTime to Permanent Discontinuation of Randomized Trial Product (Weeks)

Time to permanent discontinuation of randomised trial product from baseline (week 0) to week 44 is reported. Participants who permanently discontinued the randomised trial product during the in-trial observation period were only included in the analysis. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to date of last contact with trial site (week 51).

Time frame:
Baseline (week 0), week 44
Reported as:
Median · Weeks
Time to Permanent Discontinuation of Randomized Trial Product (Weeks)
WeeksSemaglutide 2.4 mgPlacebo
Time to Permanent Discontinuation of Randomized Trial Product (Weeks)16.7 (5.4 to 43.1)18.8 (3.0 to 43.3)
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.

Time frame:
Baseline (week 0), week 51
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsSemaglutide 2.4 mgPlacebo
Number of Treatment Emergent Adverse Events (TEAEs)1122415
SecondaryNumber of Serious Adverse Events (SAEs)

A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 51 is presented based on the on-treatment observation, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.

Time frame:
Baseline (week 0), week 51
Reported as:
Number · Events
Number of Serious Adverse Events (SAEs)
EventsSemaglutide 2.4 mgPlacebo
Number of Serious Adverse Events (SAEs)148
SecondaryNumber of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes (Yes/No) in Participants With T2D at Week 0

Hypoglycaemic episodes with onset during on-treatment observation period were considered treatment-emergent. Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemia episodes in participants with T2D at week 0 with onset during on-treatment observation period were presented.

Time frame:
Baseline (week 0), week 51
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes (Yes/No) in Participants With T2D at Week 0
EpisodesSemaglutide 2.4 mgPlacebo
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes (Yes/No) in Participants With T2D at Week 021
SecondaryChange From Baseline in Pulse

Change in pulse from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

Time frame:
Baseline (week 0), week 44
Reported as:
Mean · Beats per minute (bpm)
Change From Baseline in Pulse
Beats per minute (bpm)Semaglutide 2.4 mgPlacebo
Change From Baseline in Pulse4 ± 101 ± 10
SecondaryChange From Baseline in Amylase: Ratio to Baseline

Change in amylase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of amylase
Change From Baseline in Amylase: Ratio to Baseline
Ratio of amylaseSemaglutide 2.4 mgPlacebo
Change From Baseline in Amylase: Ratio to Baseline1.19 ± 19.41.08 ± 20.5
SecondaryChange From Baseline in Lipase: Ratio to Baseline

Change in lipase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of lipase
Change From Baseline in Lipase: Ratio to Baseline
Ratio of lipaseSemaglutide 2.4 mgPlacebo
Change From Baseline in Lipase: Ratio to Baseline1.54 ± 41.81.08 ± 37.8
SecondaryChange From Baseline in Calcitonin: Ratio to Baseline

Change in calcitonin measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.

Time frame:
Baseline (week 0), week 44
Reported as:
Geometric mean · Ratio of calcitonin
Change From Baseline in Calcitonin: Ratio to Baseline
Ratio of calcitoninSemaglutide 2.4 mgPlacebo
Change From Baseline in Calcitonin: Ratio to Baseline1.04 ± 37.00.92 ± 39.4

Adverse events

Collected over Week 0 to week 51. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sema 2.4 mg0/249 (0%)14/249 (5.6%)180/249 (72.3%)
Placebo0/126 (0%)8/126 (6.3%)57/126 (45.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventSema 2.4 mgPlacebo
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/2492/126
Upper respiratory tract infectionInfections and infestations2/2490/126
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2491/126
Gastric ulcerGastrointestinal disorders0/2491/126
GastroenteritisInfections and infestations1/2491/126
Meniscus injuryInjury, poisoning and procedural complications0/2491/126
Metabolic syndromeMetabolism and nutrition disorders0/2491/126
PyrexiaGeneral disorders0/2491/126
Abdominal pain upperGastrointestinal disorders1/2490/126
Anal abscessInfections and infestations1/2490/126
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSema 2.4 mgPlacebo
DiarrhoeaGastrointestinal disorders65/24913/126
NauseaGastrointestinal disorders60/2499/126
Upper respiratory tract infectionInfections and infestations51/24926/126
Decreased appetiteMetabolism and nutrition disorders43/2495/126
ConstipationGastrointestinal disorders29/2497/126
Abdominal distensionGastrointestinal disorders25/2491/126
VomitingGastrointestinal disorders21/2490/126
Abdominal pain upperGastrointestinal disorders15/2494/126
ArthralgiaMusculoskeletal and connective tissue disorders15/2493/126
COVID-19Infections and infestations15/2495/126

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)Semaglutide 2.4 mgPlaceboTotal
Mean41 ± 1140 ± 1141 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.4 mgPlaceboTotal
Female11159170
Male13867205
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
Hispanic or Latino261137
Not Hispanic or Latino223115338
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
American Indian or Alaska Native000
Asian225115340
Native Hawaiian or Other Pacific Islander000
Black or African American224
White22931
More than one race000
Unknown or Not Reported000
09

Study locations

33 sites
  • Instituto de Ciências Farmacêuticas de Estudos e Pesquisas
    Aparecida de Goiânia, Goiás 74935-530, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas
    São Paulo, São Paulo 01228-200, Brazil
  • The First Affiliated Hospital of Anhui Medical University-Endocrinology
    Hefei, Anhui 230061, China
  • Chinese People's Liberation Army General Hospital-Endocrinology
    Beijing, Beijing Municipality 100853, China
  • Beijing Luhe Hospital Capital Medical University
    Beijing, Beijing Municipality 101100, China
  • Beijing Pinggu Hospital-Endocrinology
    Beijing, Beijing Municipality 101200, China
  • Chongqing University Three Gorges Hospital
    Chongqing, Chongqing Municipality 404000, China
  • Fujian Medical University Union Hospital-Endocrinology
    Fuzhou, Fujian 350001, China
  • Cangzhou People's Hospital-Endocrinology
    Cangzhou, Hebei 061000, China
  • Cangzhou People's Hospital
    Cangzhou, Hebei 061000, China
  • Harrison International Peace Hospital-Endocrinology
    Hengshui, Hebei 053000, China
  • Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology
    Hengshui, Hebei 053000, China
  • The Second Hospital of Hebei Medical University-Endocrinology
    Shijiazhuang, Hebei 050000, China
  • Inner Mongolia People's Hospital-Endocrinology
    Hohhot, Inner Mongolia 010020, China
  • The affiliated Hospital of Inner Mongolia Medical University-Endocrinology
    Hohhot, Inner Mongolia 010050, China
  • Changzhou No.2 People's Hospital, Yanghu Branch
    Changzhou, Jiangsu 213003, China
  • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
    Nanjing, Jiangsu 210011, China
  • Jiangsu Province Hospital-Endocrinology
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The Affiliated Hospital of Jiangsu University-Endocrinology
    Zhenjiang, Jiangsu 212001, China
  • The First Bethune hospital of Jilin University-Endocrinology
    Changchun, Jilin 130061, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Huashan Hospital Fudan University-Endocrinology
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Tenth People's Hospital (Tenth People's of Tongji University)-Endocrinology
    Shanghai, Shanghai Municipality 200072, China
  • Shanghai Fifth People's Hospital-Endocrinology
    Shanghai, Shanghai Municipality 200240, China
  • Tongren Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200336, China
  • Shanghai Pudong New Area People's Hospital-Endocrinology
    Shanghai, Shanghai Municipality 201200, China
  • General Hospital of Tianjin Medical University-Endocrinology
    Tianjin, Tianjin Municipality 300052, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality 300211, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650101, China
  • Prince of Wales Hospital
    Shatin, New Territories, Hong Kong
  • Ajou University Hospital
    Gyeonggi-do, 16499, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
10

References and documents

Publications

  • Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, Ma RCW, Yang T, Zu N, Liu M; STEP 7 Study Group. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)00388-1. Epub 2024 Feb 5. PubMed 38330988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Aug 2022, 20 months.

Results were first posted in Nov 2024, 2 years 3 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 20 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2020
First posted
Jan 31, 2020
StartActual
Dec 8, 2020
Primary completionActual
Aug 23, 2022
CompletionActual
Aug 23, 2022
Results first posted
Nov 29, 2024
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04251156
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Dec 8, 2020
Primary completion
Aug 23, 2022
Completion
Aug 23, 2022
Results posted
Nov 29, 2024
Last update
Jan 29, 2026

Study contacts

Clinical Reporting Anchor & Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion